Diprospan injection 1ml/5 ampoules

Diprospan Composition:
active ingredient: betamethasone; 1 ml of solution contains 6.43 mg of betamethasone dipropionate (equivalent to 5 mg of betamethasone) and 2.63 mg of betamethasone sodium phosphate (equivalent to 2 mg of betamethasone) Excipients: sodium phosphate, dihydrate; sodium chloride, Trilon B; polysorbate 80 benzyl alcohol; methyl parahydroxybenzoate (E 218) propyl parahydroxybenzoate (E 216) sodium carboxymethyl cellulose; macrogols; hydrochloric acid; water for injections.

Pharmacotherapeutic group:
Corticosteroids for systemic use. Glucocorticoids. ATX code H02A B01.

Indications:
Corticosteroid therapy is an adjunct and not an alternative to conventional treatment.

Dermatological diseases Atopic dermatitis (monetary eczema), neurodermatitis, contact dermatitis, severe solar dermatitis, urticaria, lichen planus, insulin lipodystrophy, alopecia areata, discoid lupus erythematosus, psoriasis, keloid scars, pemphigus vulgaris, dermatitis herpes, cystic acne.

Rheumatic diseases Rheumatoid arthritis, osteoarthritis, bursitis, tendosynovitis, tendonitis, peritendinitis, ankylosing spondylitis, epicondylitis, sciatica, coccydynia, sciatica, lumbago, torticollis, ganglion cyst, exostoses, fasciitis, acute gouty arthritis, synovial cysts,

Morton’s disease, inflammation of the cuboid bone, diseases stop, bursitis on the background of hard calluses, spurs, stiffness of the big toe.

Allergic conditions Bronchial asthma, status asthmaticus, hay fever, severe allergic bronchitis, seasonal and aperiodic allergic rhinitis, angioedema, contact dermatitis, atopic dermatitis, serum sickness, drug hypersensitivity reactions or insect stings.

Collagen diseases Systemic lupus erythematosus, scleroderma, dermatomyositis, periarteritis nodosa.

Oncological diseases Palliative therapy for leukemia and lymphomas in adults, acute leukemia in children.

Other diseases Adrenogenital syndrome, ulcerative colitis, Crohn’s disease, sprue, pathological blood changes requiring corticosteroid therapy, nephritis, nephrotic syndrome.

Primary and secondary insufficiency of the adrenal cortex (with the mandatory simultaneous administration of mineralocorticoids).

Produced in Belgium